Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Simulations Plus to sell Words+ subsidiary to PRC
Words+ is known to provide products and services and is commited to the field of augmentative communication. Simulations Plus chairman and CEO Walt Woltosz said Words+ provides computer-based
Words+ is known to provide products and services and is commited to the field of augmentative communication. Simulations Plus chairman and CEO Walt Woltosz said Words+ provides computer-based
Scil Proteins took up the process development and early stage GMP manufacturing for a recombinant protein candidate. Scil Proteins CEO Ulrike Fiedler said the company is happy that
Fibrocaps is a dry powder topical fibrin sealant comprising of a mixture of fibrinogen and thrombin blood clotting proteins, which stop bleeding during or after surgery. The study
Almirall focuses its research resources on therapeutic areas related to the treatment of asthma, chronic obstructive pulmonary disease (COPD), gastrointestinal disorders, psoriasis and other dermatological conditions. BioFocus will
Injectafer (US brand name of Ferinject) is a non-dextran intravenous iron replacement therapy comprising Ferric carboxymaltose as the active pharmaceutical ingredient. The first trial compared Injectafer to either
The placebo-controlled, randomized study was designed to assess drug’s safety, tolerability along with pharmacokinetic parameters. In the Phase 1 SAD study, the maximum tolerated single dose was defined
The acquisition allow the company to commercialize all Shalaks’ products under the Invida brand. Invida will market Shalaks’ dermatology brands, including topical anti-acne, anti-fungal, anti-scar, anti-pigmentation, sun screens
Valsartan is a generic version of Diovan (Valsartan) and Valsartan HCTZ is the generic version Co-Diovan (Valsartan HCTZ), both of which are from Novartis and are used to
PMBL are used to prevent acute, sub-acute, recurrent or chronic infections of the upper and lower airways and the bronchopulmonary tree, in addition to acute exacerbations in chronic
Palifosfamide, a DNA cross-linker in class with bendamustine, ifosfamide and cyclophosphamide, is undergoing a randomised double-blinded placebo-controlled Phase 3 trial for the treatment of metastatic soft tissue sarcoma.